OTCMKTS:PNEXF - Pharnext Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.00
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Pharnext Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PNEXF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PNEXF

Average Price Target: $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Pharnext in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.00.

Buy

The current consensus among 2 investment analysts is to buy stock in Pharnext. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/28/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/10/2021CheuvreuxUpgradeHold ➝ Buy
10/18/2020Kepler Capital MarketsReiterated RatingHold ➝ Neutral
4/24/2020Kepler Capital MarketsDowngradeHold
(Data available from 6/20/2016 forward)
Pharnext logo
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.
Read More

Today's Range

Now: $2.00
Low: $2.00
High: $2.00

50 Day Range

MA: $3.88
Low: $2.00
High: $4.12

52 Week Range

Now: $2.00
Low: $2.00
High: $4.29

Volume

N/A

Average Volume

571 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Pharnext?

The following Wall Street research analysts have issued reports on Pharnext in the last year: Cheuvreux, and Kepler Capital Markets.
View the latest analyst ratings for PNEXF.

What is the current price target for Pharnext?

0 Wall Street analysts have set twelve-month price targets for Pharnext in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Pharnext in the next year.
View the latest price targets for PNEXF.

What is the current consensus analyst rating for Pharnext?

Pharnext currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PNEXF will outperform the market and that investors should add to their positions of Pharnext.
View the latest ratings for PNEXF.

What other companies compete with Pharnext?

How do I contact Pharnext's investor relations team?

The company's listed phone number is 33 1 41 09 22 30. The official website for Pharnext is www.pharnext.com.